1.. Introduction {#S8}
================

Inherited mutations in DNA damage repair (DDR) genes associate with an increased risk of developing prostate, breast, ovarian, and other cancers \[[@R1],[@R2]\]. We previously described enrichment of such mutations in metastatic prostate cancer (mPC), with 11.8% of these men harbouring germline DNA damage repair gene mutation (gDDRm) \[[@R3]\]. Mutations in *BRCA2* were most prevalent (5.3%), with these data leading to a change in National Comprehensive Cancer Network (NCCN) guidelines, now recommending germline testing for all men with mPC \[[@R4]\]. Studies in mPC as well as in other diseases support tailored therapeutic approaches for this molecularly defined subset of patients \[[@R5]--[@R8]\].

Characterisation of the genomic landscape of prostate cancer has led to the identification of clinically actionable molecular alterations \[[@R9],[@R10]\]. This renders an opportunity for a new classification of this common disease, beyond traditional anatomical and histological considerations, based on the prognostic and predictive significance of some of these alterations for treatment stratification.

Prior studies stated the role of germline *BRCA2* mutations are an independent poor prognostic factor for localised prostate cancer, associated with a more aggressive phenotype, increased rates of developing metastatic disease, and shorter survival from the disease \[[@R11],[@R12]\]. However, when focusing on patients with mPC, the prognostic and predictive roles of gDDRm are unclear. Prior case series have reported conflicting data with regard to the relative benefit derived for patients carrying gDDRm from standard of care therapies (taxanes, abiraterone acetate, enzalutamide) \[[@R13]--[@R15]\].

Herein, we retrospectively reviewed the clinical outcome of mPC patients with and without gDDRm. We included 372 patients from three institutions enrolled in a previously published prevalence study of gDDRm (Royal Marsden, UK; Weill-Cornell, NY; University of Washington, WA); in order to increase the number of gDDRm carriers in this analysis, we included an additional cohort of 18 known *gBRCA1*/*2*m carriers with mPC from the kConFab consortium (Australia).

2.. Patients and methods {#S9}
========================

All patients included had previously been tested for gDDRm. Germline mutations were called based on a panel of 20 genes summarised in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. For all the 372 cases from the three UK and US sites, these data had been published in a prior report, including sequencing and bioinformatics methodology \[[@R3]\]. In the original study, patients were not selected on the basis of family history, age, or any knowledge of genetic background. The remaining 18 patients were an independent cohort of known germline *BRCA1*/*2* germline mutation carriers from Australia. Patient medical records were retrospectively reviewed, and patients had received treatment according to local guidelines. Baseline characteristics (demographic characteristics, age, Gleason score, prostate-specific antigen \[PSA\] and presence of metastatic disease at diagnosis, treatment exposure, and survival data) were collected. Response data (defined as a 50% PSA fall from baseline and/or radiological response according to RECIST) and progression-free survival (PFS; defined as the time from start of a treatment to RECIST/PSA progression or start of a new therapy for clinical progression) for abiraterone, enzalutamide, and docetaxel were annotated.

To account for potential differences between the cohorts, a mixed-effect parametric survival model (Weibull distribution) with random intercept per cohort was used to study correlations with clinical outcome. Multivariate analyses adjusted for age, Gleason score, metastatic disease at diagnosis, and prior radical treatment at diagnosis (either radical prostatectomy or radiotherapy). Fisher's exact test was used to study response rates to each therapy. A test for interaction was pursued for an exploratory subgroup analysis assessing the impact of PARP inhibitors (PARPi) and/or platinum therapy on patient outcome. Kaplan--Meier curves were used to represent time to event data.

3.. Results {#S10}
===========

3.1.. Baseline characteristics and treatment exposure {#S11}
-----------------------------------------------------

Clinical data were available for 390 patients including 330 not found to carry gDDRm (gDDRm--) and 60 cases with presence of gDDRm (gDDRm+). The distribution of genes mutated per case within the gDDRm+ group was as follows: *BRCA2*: 37; *ATM*: seven; *CHEK2*: four; *BRCA1*, *PALB2*, *RAD51D*: two each; others: seven (one patient had both *ATM* and *CHEK2* mutations; [Supplementary Tables 2](#SD1){ref-type="supplementary-material"} and [3](#SD1){ref-type="supplementary-material"}). There were no significant differences in baseline characteristics based on gDDRm status ([Table 1](#T1){ref-type="table"}), including age at diagnosis (median of 62.6 vs 64.9 yr for gDDRm+ vs gDDRm--). Overall, 74% and 69% of patients received, respectively, docetaxel and novel androgen receptor signalling inhibitors (ARSIs: abiraterone acetate, enzalutamide) for metastatic castration-resistant prostate cancer (mCRPC). Based on the cross resistance demonstrated between abiraterone acetate and enzalutamide, in this analysis we considered only the first exposure to either abiraterone acetate or enzalutamide. Of note, 28/60 (47%) gDDRm+ and 113/330 (34%) gDDRm--patients also received treatment with PARPi and/or platinum chemotherapy, treatments that are not currently routinely used for prostate cancer care, reflecting the research focus of the involved academic groups.

3.2.. Prognosis of patients with gDDRm {#S12}
--------------------------------------

Overall survival (OS) was similar in the two subgroups, with 296 death events (75% of the study population), median OS from castration resistance was 3.0 yr for gDDRm+ (inter-quartile range \[IQR\] 2.4--5.6), 3.0 yr for *gBRCA2*+ (IQR 2.5--5.4), and 3.2 yr for gDDRm- (IQR 1.7--5.5; log-rank test *p* = 0.73). In multivariate analysis, age at diagnosis (per 10 yr older, adjusted hazard ratio \[aHR\] 1.45, 95% confidence interval \[CI\] 1.21--1.73; *p* \< 0.001), and Gleason score ≥8 (aHR 1.54, 95% CI 1.16--2.04; *p* = 0.003), but not germline mutations (aHR 0.93, 95% CI 0.63--1.37; *p* = 0.72) were associated with worse survival. When looking specifically at the impact of germline *BRCA2* mutations, these were also not associated with a significantly different prognosis (aHR 0.83, 95% CI 0.50--1.36, *p* = 0.45; [Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

3.3.. gDDRm and docetaxel {#S13}
-------------------------

On docetaxel chemotherapy, gDDRm did not associate with significantly different PFS (HR 0.86, 95% CI 0.61--1.20, *p* = 0.37); similar results were observed when evaluating germline *BRCA2* mutation carriers alone (HR 0.96, 95% CI 0.64--1.43, *p* = 0.83). Kaplan--Meier curves for PFS on docetaxel are shown in [Figure 2](#F2){ref-type="fig"}. Response rate to docetaxel was 61% and 54% for gDDR+ and gDDR- patients, respectively (Fisher's exact *p* = 0.48, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}); this resulted in an odds ratio of response to docetaxel of 1.33 (95% CI 0.66--2.69; *p* = 0.43) for patients carrying gDDRm compared with gDDRm- patients.

3.4.. gDDRm and ARSIs (abiraterone, enzalutamide) {#S14}
-------------------------------------------------

PFS on first ARSI (either abiraterone or enzalutamide) for mCRPC was not significantly different for patients with or without gDDRm (HR 0.93, 95% CI 0.65--1.32, *p* = 0.67), with similar median PFS for gDDRm+ (8.3 mo) and gDDRm- (8.3 mo; [Fig. 2](#F2){ref-type="fig"}). Patients with *BRCA2* mutations also had similar PFS to the overall population (HR 1.09, 95% CI 0.72--1.67, *p* = 0.66). Response rates to the first ARSI were 46% and 56% for gDDRm+ and gDDRm- patients, respectively (Fisher's exact *p* = 0.28, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}), resulting in a nonsignificant trend towards a lower chance of response for gDDRm+ (odds ratio 0.65, 95% CI 0.32--1.32, *p* = 0.23).

3.5.. PARPi and platinum in patients with gDDRm {#S15}
-----------------------------------------------

In this cohort, 141 (36%) patients had received PARPi and/or platinum chemotherapy, including 28/60 (47%) gDDRm+ cases. We explored the potential interaction of these treatments and gDDRm on survival from castration resistance in this cohort.

There was no statistically significant impact from PARPi/platinum on OS for the overall population (aHR 0.97, 95% CI 0.73--1.31; *p* = 0.88). The hazard of death based on the presence of gDDR mutations once adjusted for exposure to PARPi/platinum indicated no statistically significant difference in risk of death (aHR 1.23; 95% CI 0.73--2.07; *p* = 0.44).

An interaction test between gDDRm+ and PARPi/platinum therapy revealed an aHR of 0.59 (95% CI 0.28--1.25; *p* = 0.17). These data suggest that the association of gDDRm status and survival could have been impacted by the exposure to PARPi/platinum. Nevertheless, with this size of the gDDRm+ subgroup, no statistically significant differences were observed in this cohort and the null hypothesis could not be excluded. Survival curves illustrating the impact of PARPi/platinum by gDDRm status are shown in [Figure 3](#F3){ref-type="fig"}.

4.. Discussion {#S16}
==============

In this study, we retrospectively reviewed clinical outcome of lethal prostate cancer patients according to their gDDRm status \[[@R3]\]. Overall, we did not observe significant differences in response rate and PFS from docetaxel and ARSIs based on gDDRm status, suggesting that gDDRm+ carriers derive benefit from these therapies similarly to the overall population. These data are of major interest to the clinical community at this time in view of changes in NCCN guidelines in 2018 recommending germline testing for all men suffering from mPC \[[@R4]\].

Prior analyses interrogating this question have reported conflicting results. A recent retrospective study including 319 patients (22 gDDRm+, 16 being germline *BRCA2* mutation carriers) reported shorter OS and worse outcome from abiraterone/enzalutamide treatment, but not from docetaxel for mCRPC patients with gDDRm \[[@R13]\]. Preliminary results of a prospective clinical trial of abiraterone and the PARP inhibitor veliparib suggested conversely that prostate cancer patients with DDR defects (here including germline and somatic alterations) may actually be more likely to respond to abiraterone acetate therapy \[[@R16]\]. Differences in the baseline characteristics, genes included in each analysis, and distribution and prevalence of mutations between study populations may have accounted for these differences. The retrospective nature of ours and other studies is a significant limitation, and prospective validation is required in ongoing studies \[[@R15]\]. Data from breast cancer studies also suggest that patients with germline *BRCA1*/*2* mutations derive significant benefit from taxane-based chemotherapy \[[@R17]\].

A notable distinction of our patient cohort was the substantial proportion of patients treated with PARP inhibitors and/or platinum chemotherapy, which are not part of the standard of care for prostate cancer. This has to be taken into account when comparing the survival analysis in this study to others, since the introduction of these treatments may have impacted outcome. The use of such therapies should not, however, have impacted response data to the specific standard therapies presented here, since these were largely administered prior to the PARP inhibitor or platinum therapy. We observed a trend towards prolonged OS in gDDRm+ patients receiving PARPi/platinum. This interaction was not, however, statistically significant in this small gDDRm+ cohort, and may be a chance finding or have been impacted by other unrecognised confounding factors \[[@R7],[@R8]\].

Another limitation of our study is the focus on germline, to the exclusion of somatic only, mutations \[[@R9],[@R18],[@R19]\]. It is estimated that 20--25% mPC have somatic inactivation of a DNA repair gene, but just less than half of these carry a germline mutation. Hence, it is likely that a substantial proportion of our cases in the gDDRm- group harboured somatic DDR defects and that some but not all the gDDRm+ cases would have had somatic inactivation of the second allele. Moreover, the lack of somatic DNA data for this cohort also prevented us from analysing the impact of other concurrent genomic events influencing prostate cancer progression, such as *AR*, *TP53*, or *RB1* aberrations. Studies assessing clinical outcome to specific therapies incorporating somatic genomic data are ongoing and will be fundamental to shape precision medicine strategies in mCRPC and complement ongoing clinical trials of DNA repair targeting agents in CRPC. These studies and prospective clinical trials will also need to control for other potential prognostic factors not assessed in this retrospective study.

5.. Conclusions {#S17}
===============

The data presented here suggest that mPC patients with inherited mutations in DDR genes, including those with *BRCA2* mutations, can derive similar benefit from standard of care therapies in terms of both response rate and PFS. Based on the limitations described, we acknowledge that this study may not be sufficient to fully inform clinical decisions; in view of the discrepancies identified among different retrospective analyses, prospective studies are now needed evaluating the impact of germline DNA repair mutations in advanced prostate cancer, beyond their clear importance to prompt family cascade counselling. Nevertheless, our overall data indicate that detection of gDDRm should not preclude mPC patients from receiving taxanes, abiraterone, and enzalutamide as standards of care. Pivotal clinical trials of PARPi are ongoing for prostate cancer sufferers with germline and somatic DDRm, and may offer additional therapy options for this group of patients.
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![Kaplan--Meier curves for survival from date of castration resistance and from initial diagnosis based on the presence of gDDRm and specifically for gBRCA2m carriers. CRPC = castration-resistant prostate cancer; gDDRm = germline DNA damage repair gene mutation; IQR = interquartile range.](nihms-1050003-f0001){#F1}

![Kaplan--Meier curves for progression-free survival on docetaxel and first-line ARSI therapy based on the presence of any gDDRm. ARSI = androgen receptor signalling inhibitor; gDDRm = germline DNA damage repair gene mutation; IQR = interquartile range; PFS = progression-free survival.](nihms-1050003-f0002){#F2}

![Kaplan--Meier curves depicting survival from detection of castration resistance, with patients grouped by exposure to PARP inhibitors and/or platinum therapy for (A) gDDRm+ or (B) gDDRm- metastatic castration-resistant prostate cancers. Dashed lines indicate the 95%CI limits. CI = confidence interval; CRPC = castration-resistant prostate cancer; gDDR = germline DNA damage repair; gDDRm = germline DNA damage repair gene mutation; IQR = interquartile range; PARPi = PARP inhibitor.](nihms-1050003-f0003){#F3}

###### 

Baseline characteristics of the study population (*n* = 390)

                                    Patients with any germline mutation (*n* = 60)   Patients without germline mutation (*n* = 330)   *p* value^[a](#TFN2){ref-type="table-fn"}^                
  --------------------------------- ------------------------------------------------ ------------------------------------------------ -------------------------------------------- ------------ --------------------------------------------
  Gleason score                                                                                                                                                                                 
   5--7                             15                                               28.9                                             105                                          37.5         0.27
   8--10                            37                                               71.2                                             175                                          62.5         
  Metastatic disease at diagnosis                                                                                                                                                               
   No                               34                                               58.6                                             173                                          53.7         0.57
   Yes                              24                                               41.4                                             149                                          46.3         
  Received radical treatment                                                                                                                                                                    
   No                               22                                               36.7                                             140                                          42.4         0.48
   Yes                              38                                               58.5                                             190                                          57.6         
  Docetaxel                                                                                                                                                                                     
   No                               16                                               26.7                                             88                                           26.7         1.00
   Yes                              44                                               73.3                                             242                                          73.3         
  Abiraterone and/or enzalutamide                                                                                                                                                               
   No                               18                                               30                                               101                                          30.6         1.00
   Yes                              42                                               70                                               229                                          69.4         
  PARPi and/or platinum                                                                                                                                                                         
   No                               32                                               53.3                                             217                                          65.8         0.08
   Yes                              28                                               46.7                                             113                                          34.2         
  Radium-223                                                                                                                                                                                    
   No                               52                                               86.7                                             296                                          90.2         0.37
   Yes                              8                                                13.3                                             32                                           9.8          
                                    Median                                           Q1--Q3                                           Median                                       Q1--Q3       *p* value^[b](#TFN3){ref-type="table-fn"}^
  Age at diagnosis (yr)             62.6                                             55.3--66.2                                       62.4                                         57.7--68.5   0.24
  PSA (ng/dl)                       17.2                                             7.7--109.6                                       33.0                                         9.8--148.3   0.34

PARPi = PARP inhibitors; PSA = prostate-specific antigen.

Fisher's exact test.

Wilcoxon rank sum test.

###### 

Overall survival from castration resistance and progression-free survival to standard therapies

                                  aHR (MVA)   95% CI       *p* value
  ------------------------------- ----------- ------------ -----------
  OS from castration resistance                            
   Any gDDRm+                     0.93        0.63--1.37   0.72
   Age at diagnosis (per 10 yr)   1.45        1.22--1.73   \<0.001
   Gleason 8--10                  1.54        1.16--2.04   0.003
   Metastatic disease             1.22        0.84--1.75   0.30
   Radical treatment              1.50        1.03--2.18   0.03
                                  HR          95% CI       *p* value
  PFS docetaxel                                            
   Any gDDRm +                    0.86        0.61--1.20   0.37
   Only gBRCA2m+                  0.96        0.64--1.43   0.83
  PFS first line of ARS therapy                            
   Any gDDRm +                    0.96        0.69--1.35   0.83
   Only gBRCA2m+                  1.10        0.72--1.67   0.67

aHR = adjusted hazard ratio; ARS = androgen receptor signal; CI = confidence interval; gDDRm = germline DNA damage repair gene mutation; MVA = multivariate analysis; PSA = prostate-specific antigen. Results from a mixed-effect survival model (Weibull distribution) with random intercept per cohort.
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